225 related articles for article (PubMed ID: 29102175)
1. Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4.
Li C; Shan Y; Sun Y; Si R; Liang L; Pan X; Wang B; Zhang J
Eur J Med Chem; 2017 Dec; 141():506-518. PubMed ID: 29102175
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
Sun Y; Shan Y; Li C; Si R; Pan X; Wang B; Zhang J
Eur J Med Chem; 2017 Dec; 141():373-385. PubMed ID: 29032031
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel anti-angiogenesis agents. Part 10: Multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol.
Pan X; Liang L; Si R; Wang J; Zhang Q; Zhou H; Zhang L; Zhang J
Eur J Med Chem; 2019 Feb; 163():1-9. PubMed ID: 30503935
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel anti-angiogenesis agents. Part 9: Multiplex inhibitors suppressing compensatory activations of RTKs.
Shan Y; Si R; Wang J; Zhang Q; Zhou H; Song J; Zhang J; Chen Q
Eur J Med Chem; 2019 Feb; 164():440-447. PubMed ID: 30616052
[TBL] [Abstract][Full Text] [Related]
5. Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect.
Sana S; Reddy VG; Bhandari S; Reddy TS; Tokala R; Sakla AP; Bhargava SK; Shankaraiah N
Eur J Med Chem; 2020 Aug; 200():112457. PubMed ID: 32422489
[TBL] [Abstract][Full Text] [Related]
6. Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents.
Wang J; Zhang L; Pan X; Dai B; Sun Y; Li C; Zhang J
Sci Rep; 2017 Mar; 7():45145. PubMed ID: 28332573
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel VEGFR-2 inhibitors. Part 5: Exploration of diverse hinge-binding fragments via core-refining approach.
Shan Y; Gao H; Shao X; Wang J; Pan X; Zhang J
Eur J Med Chem; 2015 Oct; 103():80-90. PubMed ID: 26342134
[TBL] [Abstract][Full Text] [Related]
8. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
[TBL] [Abstract][Full Text] [Related]
9. Double-edged Swords: Diaryl pyrazoline thiazolidinediones synchronously targeting cancer epigenetics and angiogenesis.
Upadhyay N; Tilekar K; Safuan S; Kumar AP; Schweipert M; Meyer-Almes FJ; Ramaa CS
Bioorg Chem; 2021 Nov; 116():105350. PubMed ID: 34547645
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel thiophene-3-carboxamide derivatives as potential VEGFR-2 inhibitors with anti-angiogenic properties.
Li T; Wang J; Feng L; Zhou Q; Xie Q; Shen Y; Ji R; Liu X; Wang Y; Hu C
Bioorg Chem; 2024 Jun; 147():107358. PubMed ID: 38626490
[TBL] [Abstract][Full Text] [Related]
11. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
[TBL] [Abstract][Full Text] [Related]
12. Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
Pavana RK; Choudhary S; Bastian A; Ihnat MA; Bai R; Hamel E; Gangjee A
Bioorg Med Chem; 2017 Jan; 25(2):545-556. PubMed ID: 27894589
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.
Yuan X; Yang Q; Liu T; Li K; Liu Y; Zhu C; Zhang Z; Li L; Zhang C; Xie M; Lin J; Zhang J; Jin Y
Eur J Med Chem; 2019 Oct; 179():147-165. PubMed ID: 31252306
[TBL] [Abstract][Full Text] [Related]
14. Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents.
Zhang L; Shan Y; Ji X; Zhu M; Li C; Sun Y; Si R; Pan X; Wang J; Ma W; Dai B; Wang B; Zhang J
Oncotarget; 2017 Dec; 8(62):104745-104760. PubMed ID: 29285210
[TBL] [Abstract][Full Text] [Related]
15. New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation.
Abdel-Mohsen HT; Girgis AS; Mahmoud AEE; Ali MM; El Diwani HI
Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900089. PubMed ID: 31463965
[TBL] [Abstract][Full Text] [Related]
16. Discovery and molecular docking of quinolyl-thienyl chalcones as anti-angiogenic agents targeting VEGFR-2 tyrosine kinase.
Rizvi SU; Siddiqui HL; Nisar M; Khan N; Khan I
Bioorg Med Chem Lett; 2012 Jan; 22(2):942-4. PubMed ID: 22200597
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
Ravez S; Barczyk A; Six P; Cagnon A; Garofalo A; Goossens L; Depreux P
Eur J Med Chem; 2014 May; 79():369-81. PubMed ID: 24747748
[TBL] [Abstract][Full Text] [Related]
18. Quinoxalinone (Part II). Discovery of (Z)-3-(2-(pyridin-4-yl)vinyl)quinoxalinone derivates as potent VEGFR-2 kinase inhibitors.
Shi L; Zhou J; Wu J; Cao J; Shen Y; Zhou H; Li X
Bioorg Med Chem; 2016 Apr; 24(8):1840-52. PubMed ID: 26968648
[TBL] [Abstract][Full Text] [Related]
19. Pyrazolo-benzothiazole hybrids: Synthesis, anticancer properties and evaluation of antiangiogenic activity using in vitro VEGFR-2 kinase and in vivo transgenic zebrafish model.
Reddy VG; Reddy TS; Jadala C; Reddy MS; Sultana F; Akunuri R; Bhargava SK; Wlodkowic D; Srihari P; Kamal A
Eur J Med Chem; 2019 Nov; 182():111609. PubMed ID: 31445229
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.
Dandu R; Zulli AL; Bacon ER; Underiner T; Robinson C; Chang H; Miknyoczki S; Grobelny J; Ruggeri BA; Yang S; Albom MS; Angeles TS; Aimone LD; Hudkins RL
Bioorg Med Chem Lett; 2008 Mar; 18(6):1916-21. PubMed ID: 18308565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]